



PCT  
JC10 Rec'd T/PTO 15 JUL 2005  
#2

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q86357

Tetsuro KIKUCHI, et al.

Appln. No.: 10/540,577

Confirmation No.: Not Yet Assigned

Group Art Unit: Not Yet Assigned

Filed: June 24, 2005

Examiner: Not Yet Assigned

For: CARBOSTYRIL DERIVATIVES AND SEROTONIN REUPTAKE INHIBITORS FOR  
TREATMENT OF MOOD DISORDERS

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby  
notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached  
PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem  
material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following:  
U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications  
filed after June 30, 2003. A copy of the International Search Report is also being submitted.  
The documents listed on Sheet 1 of the Form PTO/SB/08 are the ISR documents. The  
documents on Sheets 2-5 are additional documents not listed on the ISR.

INFORMATION DISCLOSURE STATEMENT


U.S. Appln. No.: 10/540,577

Attorney Docket No.: Q86357

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

Respectfully submitted,



Brett S. Sylvester  
Registration No. 32,765

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE  
23373  
CUSTOMER NUMBER

Date: July 15, 2005

Substitute for Form 1449 A & B/PTO <b>OPPE</b> <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>		<i>Complete if Known</i>	
JUL 15 2015 SEARCHED INDEXED MAILED 1 of 5		Application Number	10/540,577
		Confirmation Number	
		Filing Date	June 24, 2005
		First Named Inventor	Tetsuro KIKUCHI
		Art Unit	
		Examiner Name	
		Attorney Docket Number	Q86357

U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Name of Patentee or Applicant of Cited Document
		Number	Kind Code <sup>2</sup> (if known)	
/S.R.G./	1	US 2002/0156067	A1	10-24-2002 Wong, et al.

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation <sup>4</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>			
/S.R.G./	2	WO	02/060423	A2 08-08-2002	Otsuka Pharmaceutical Co., Ltd.	
/S.R.G./	8	WO	2004/010932	A2 02-05-2004	Peter Migaly	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.				Translation <sup>4</sup>
/S.R.G./	3	CINDY P. LAWLER, et al., Interactions of the Novel Antipsychotic Aripiprazole (OPC-14597) with Dopamine and Serotonin Receptor Subtypes, <i>Neuropsychopharmacology</i> , 1999, vol. 20, no. 6, pp. 612-627				
/S.R.G./	4	KEVIN D. BURRIS, et al., Aripiprazole, a Novel Antipsychotic, is a High-Affinity Partial Agonist at Human Dopamine D2 Receptors, <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 2002, vol. 302, no. 1, pp. 381-389				
/S.R.G./	5	GOODMAN et al., "The Pharmacological Basis of Therapeutics", 2001, vol. ed. 10, p. 451 and p. 468				
/S.R.G./	6	SHELDON H. PRESKORN, Relating Clinical Trials to Psychiatric Practice: Part I: The Case of a 13-Year Old on Aripiprazole and Fluoxetine, <i>Journal of Psychiatric Practice</i> , 2003, vol. 9, no. 4, pp. 307-313				
/S.R.G./	7	BEN GREEN, Focus on aripiprazole, <i>Current Medical Research and Opinions</i> , 2004, vol. 20, no. 2, pp. 207-213				

Examiner Signature	/Shelley R. Graham/	Date Considered	01/23/2008
--------------------	---------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov), MPEP 901.04 or in the comment box of this document. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to indicate here if English language Translation is attached.

Substitute for Form 1449 A &amp; B/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

5

Complete if Known

Application Number	10/540,577
Confirmation Number	
Filing Date	June 24, 2005
First Named Inventor	Tetsuro KIKUCHI
Art Unit	
Examiner Name	
Attorney Docket Number	Q86357

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code <sup>3</sup> (if known)		
/S.R.G./	9	US 6,147,072		11-14-2000	Bymaster et al.
	10	US 2003/0027817		02-06-2003	Tollefson
	12	US 2002/0123490		09-05-2002	Howard, JR.
	33	US 5,958,921		09-28-1999	Tollefson
	36	US 2002/0156067		10-24-2002	Wong et al.
	37	US 2003/0109546		06-12-2003	Fenton
	39	US 5,945,416		08-31-1999	Shannon et al.
	41	US 2003/0130334		07-10-2003	Muller
/S.R.G./	44	US 60/473,378		05-23-2003	Tetsuro Kikuchi et al.

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation <sup>4</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>3</sup> (if known)			
/S.R.G./	11	EP	958824		11-24-1999	Eli Lilly & Co.	

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation <sup>4</sup>
/S.R.G./	13	ROTHSCHILD, Management of Psychotic Treatment-Resistant Depression, The Psychiatric Clinics of North America, 1996, vol. 19, no. 2, pp. 237-252	
	14	WOLFERSDORF, et al., Pharmacotherapy of Delusional Depression: Experience with Combinations of Antidepressants with the Neuroleptics Zoltepine and Haloperidol, Neuropsychobiology, 1994, vol. 29, pp. 189-193	
	15	WOLFERSDORF, et al., Paroxetine as Antidepressant in Combined Antidepressant-neuroleptic Therapy in Delusional Depression: Observation of Clinical Use, Pharmacopsychiatry, 1995, vol. 28, no. 2, pp. 56-60	
	16	CZYRAK, et al., Pharmacological Effects of Zoltepine and other Antipsychotics on the Central 5-HT <sub>2</sub> Receptors, Pharmacopsychiatry, 1993, vol. 26, no. 2, pp. 53-58	
	17	MCELROY, et al., Clozapine in the Treatment of Psychotic Mood Disorders, Schizoaffective Disorder, and Schizophrenia, Journal of Clinical Psychiatry, 1991, vol. 52, no. 10, pp. 411-414	
	18	MELTZER, et al., Psychopharmacology, The Third Generation of Progress, 1987, pp. 1021-1029 and 1031-1049	
	19	BERNSTEIN, J.G., Induction of obesity by psychotropic drugs, Ann. NY Acad. Sci., 1987, vol. 499, pp. 203-215	
/S.R.G./	20	BERNSTEIN, J.G., Psychotropic drug induced weight gain: mechanisms and management, Clinical Neuropharmacology, 1988, vol. 11, suppl. 1, s194-206	

Examiner Signature	/Shelley R. Graham/	Date Considered	01/23/2008
--------------------	---------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov), MPEP 901.04 or in the comment box of this document. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to indicate here if English language Translation is attached.

Substitute for Form 1449 A & B/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>		Application Number	10/540,577
		Confirmation Number	/
		Filing Date	June 24, 2005
		First Named Inventor	Tetsuro KIKUCHI
		Art Unit	
		Examiner Name	
		Attorney Docket Number	Q86357
Sheet	3	of	5

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code <sup>1</sup> (if known)		
		US			

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation <sup>6</sup>
		Country Code <sup>2</sup>	Number <sup>4</sup>	Kind Code <sup>3</sup> (if known)			

## NON-PATENT LITERATURE DOCUMENTS

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages), volume-issue number(s), publisher, city, and/or country where published.	Translation*
/S.R.G./	21	JACOBSEN, Risperidone in the Treatment of Affective Illness and Obsessive-Compulsive Disorder, Journal of Clinical Psychiatry, 1995, vol. 56, no. 9, pp. 423-429	
	22	CENTORRINO, et al., Serum Levels of Clozapine and Norclozapine in Patients Treated With Selective Serotonin Reuptake Inhibitors, American Journal of Psychiatry, 1996, vol. 153, no. 6, pp. 820-822	
	23	SAXENA, et al., Risperidone Augmentation of SRI Treatment for Refractory Obsessive-Compulsive Disorder, J. Clin. Psychiatry, 1996, vol. 57, pp. 303-306	
	24	WEISLER, et al., Adjuvantive Use of Olanzapine in Mood Disorders: Five Case Reports, Annals of Clinical Psychiatry, 1997, vol. 9, no. 4, pp. 259-262	
	25	O'CONNOR, Adding Risperidone to Selective Serotonin Reuptake Inhibitor Improves Chronic Depression, Journal of Clinical Psychopharmacology, 1998, vol. 18, no. 1, pp. 89-91	
/S.R.G./	26	MARSHALL, et al., Bupropion and sertraline combination treatment in refractory depression, J. Psychopharmacology, 1995, vol. 9, no. 3, pp. 284-286	

Examiner Signature	/Shelley R. Graham/	Date Considered	01/23/2008
--------------------	---------------------	-----------------	------------

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Office that issued the document, by the two-letter code (WIPO Standard ST. 3).<sup>3</sup> For Japanese patent documents, the indication of the year or the reign of the Emperor must precede the serial number of the patent document.<sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if applicable.<sup>5</sup> Applicant is to indicate here if English language Translation is attached.

Substitute for Form 1449 A &amp; B/PTO

Complete if Known

Application Number	10/540,577
Confirmation Number	
Filing Date	June 24, 2005
First Named Inventor	Tetsuro KIKUCHI
Art Unit	
Examiner Name	
Attorney Docket Number	Q86357

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

4

of 5



## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code <sup>2</sup> (if known)		
	US				

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation <sup>4</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation <sup>4</sup>
/S.R.G./	27	ARMSTRONG, et al., Blood Clozapine Levels Elevated by Fluvoxamine: Potential for Side Effects and Lower Clozapine Dosage, <i>Journal of Clinical Psychiatry</i> , 1997, vol. 58, no. 11, p. 499	
/S.R.G./	28	WHITE, et al., Seizure Resulting From A Venlafaxine Overdose, <i>The Annals of Pharmacotherapy</i> , 1997, vol. 31, no. 2, pp. 178-180	
/S.R.G./	29	TOHEN, et al., Olanzapine versus placebo in the treatment of acute mania, <i>Eur. Neuropsychopharmacol.</i> , 1998, vol. 8, no. suppl. 2, s178	
/S.R.G./	30	NEMEROFF, Augmentation Strategies in Patients with Refractory Depression, Depression and Anxiety, 1996-1997, vol. 4, no. 4, pp. 169-181	
/S.R.G./	31	NELSON, Overcoming Treatment Resistance in Depression, <i>Journal of Clinical Psychiatry</i> , 1998, vol. 59, suppl. 16, pp. 13-19	
/S.R.G./	32	BODKIN, et al., Combining Serotonin Reuptake Inhibitors and Bupropion in Partial Responders to Antidepressant Monotherapy, <i>Journal of Clinical Psychiatry</i> , 1997, vol. 58, no. 4, pp. 137-145	

Examiner Signature	/Shelley R. Graham/	Date Considered	01/23/2008
--------------------	---------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov). MPEP 901.04 or in the comment box of this document. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to indicate here if English language Translation is attached.

Substitute for Form 1449 A & B/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/540,577
(use as many sheets as necessary)				Confirmation Number	
				Filing Date	June 24, 2005
				First Named Inventor	Tetsuro KIKUCHI
				Art Unit	
				Examiner Name	
				Attorney Docket Number	Q86357
Sheet		5	of	5	

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code <sup>3</sup> (if known)		
44	US 60/473,378			05-23-2003	Tetsuro Kikuchi, et al.

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation <sup>4</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>3</sup> (if known)			

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation <sup>4</sup>
34	SHELTON, et al., A Novel Augmentation Strategy for Treating Resistant Major Depression, American Journal of Psychiatry, 2001, vol. 158, no. 1, pp. 131-134		
35	CASSIDY, et al., Addition of Fluoxetine to Clozapine, American Journal of Psychiatry, 1992, vol. 149, no. 9, p. 1274		
38	CITROME, et al., Pharmacokinetics and safety of aripiprazole and concomitant mood stabilizers, Neuropsychopharmacology, 2002, vol. 5, suppl. 1		
40	Therapie, 1999, vol. 54, no. 2, pp. 267-269		
42	MÖLLER, et al., Treatment of Bipolar Disorder, J. Clin. Psychiatry, 2003, vol. 64, suppl. 6, pp. 9-17		
43	KOWATCH, et al., The Use of Mood Stabilizers and Atypical Antipsychotics in Children and Adolescents With Bipolar Disorders, CNS Spectrums, 2003, vol. 8, no. 4, pp. 273-280		
45	WORTHINGTON, et al., Aripiprazole as Augmentor of SSRIs in Mood and Anxiety Disorders Patients, American Psychiatric Association 2003 Annual Meeting, May 17-22, 2003 (poster, May 19, 2003) (summary of the abstract, May 17, 2003) (meeting program, May 17, 2003)		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov), MPEP 901.04 or in the comment box of this document. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to indicate here if English language Translation is attached.